Cochlear Limited (OTCMKTS:CHEOY - Get Free Report)'s share price shot up 1.7% on Wednesday . The company traded as high as $85.75 and last traded at $85.19. 8,069 shares traded hands during mid-day trading, a decline of 51% from the average session volume of 16,362 shares. The stock had previously closed at $83.75.
Wall Street Analysts Forecast Growth
Separately, The Goldman Sachs Group initiated coverage on shares of Cochlear in a research note on Thursday, January 16th. They set a "neutral" rating for the company.
Get Our Latest Stock Report on CHEOY
Cochlear Stock Performance
The business has a 50 day moving average price of $87.81 and a 200-day moving average price of $92.99.
Cochlear Increases Dividend
The company also recently disclosed a dividend, which will be paid on Tuesday, April 29th. Shareholders of record on Friday, March 21st will be paid a dividend of $0.6165 per share. This is a positive change from Cochlear's previous dividend of $0.14. The ex-dividend date of this dividend is Friday, March 21st.
Cochlear Company Profile
(
Get Free Report)
Cochlear Limited provides implantable hearing solutions for children and adults worldwide. It offers cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.
Featured Articles
Before you consider Cochlear, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cochlear wasn't on the list.
While Cochlear currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
